A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline

Last updated: January 22, 2024
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Overall Status: Terminated

Phase

1

Condition

Stress

Post-traumatic Stress Disorders

Treatment

Prazosin

Propranolol

Clinical Study ID

NCT05189977
331-201-00246
  • Ages 18-65
  • All Genders

Study Summary

A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Primary Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition criteria Diagnosis of Major Depressive Disorder, post-traumatic stress disorder, generalized anxiety disorder, panic disorder, social anxiety disorder or obsessive-compulsive disorder

  • Must be able to receive a sertraline dose of 150 mg/day by the second screening visit (Day -15)

Exclusion Criteria

  • Sexually active males or females, who could become pregnant, not agreeing to practice 2 different methods of birth control or remain abstinent during the trial and for 30 days at the end of the study

  • Diagnosed hypertension (including treated or untreated hypertension), or orthostatic hypotension

  • Epilepsy or a history of seizures

  • History of neuroleptic malignant syndrome or serotonin syndrome.

  • Primary DSM-5 diagnosis of Schizophrenia spectrum and other psychotic disorders, Bipolar and related disorders, Feeding and eating disorders (including anorexia nervosa or bulimia), Neurocognitive disorders (including but not limited to delirium, major or mild neurocognitive disorder due to Alzheimer's, Parkinson's, or traumatic brain injury)

  • A significant risk of committing violent acts, serious self-harm, or suicide

  • History of diabetes mellitus (type 1 or type 2)

  • Subjects with any previous exposure to brexpiprazole, or subjects with chronic use of prazosin or propranolol in the 90 days prior to the screening visit or any use in the 21 days (3 weeks) prior to the screening visit.

Study Design

Total Participants: 34
Treatment Group(s): 2
Primary Treatment: Prazosin
Phase: 1
Study Start date:
September 07, 2022
Estimated Completion Date:
August 03, 2023

Connect with a study center

  • For additional information regarding sites (California, Texas, New Jersey, Minnesota)

    Princeton, New Jersey 08540
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.